JSPR Share Price Performance
US$2.45
-13.97 (-85.08%)
Price US$2.45
Share PriceUS$2.45
JSPR Community Narratives
There are no narratives available yet.
Recent JSPR News & Updates
No updates
Jasper Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -5.24
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Jasper Therapeutics, Inc. Competitors
About JSPR
- Founded
- n/a
- Employees
- 64
- CEO
- WebsiteView website
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. More promisingly, the market is up 20% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading